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Abstract

Author Manuscript

Major depressive disorder (MDD) is a common and potentially life-threatening mood disorder.
Identifying genetic markers for depression might provide reliable indicators of depression risk,
which would, in turn, substantially improve detection, enabling earlier and more effective
treatment. The aim of this study was to identify rare variants for depression, modeled as a
continuous trait, using linkage and post-hoc association analysis. The sample comprised 1221
Mexican-American individuals from extended pedigrees. A single dimensional scale of MDD was
derived using confirmatory factor analysis applied to all items from the Past Major Depressive
Episode section of the Mini-International Neuropsychiatric Interview. Scores on this scale of
depression were subjected to linkage analysis followed by QTL region-specific association
analysis. Linkage analysis revealed a single genome-wide significant QTL (LOD = 3.43) on
10q26.13, QTL-specific association analysis conducted in the entire sample revealed a suggestive
variant within an intron of the gene LHPP (rs11245316, p = 7.8×10-04; LD-adjusted Bonferronicorrected p = 8.6×10-05). This region of the genome has previously been implicated in the etiology
of MDD; the present study extends our understanding of the involvement of this region by
highlighting a putative gene of interest (LHPP).
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Introduction
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Major depressive disorder (MDD) is a common and potentially life-threatening mood
disorder 1. It affects 16.2% of individuals in the US during their lifetime 2, and incurs great
economic cost ($83.1 billion per annum in the US) 3. The illness also places an immense
burden on the sufferer, such that the impact of MDD on wellbeing and functioning is in line
with that seen in other major chronic conditions (e.g., arthritis and diabetes mellitus) 4.
Moreover, functional impairments remain even after the remission of a depressive episode 5.
Unsurprisingly, the World Health Organization (WHO) cites MDD as a leading cause of
disability worldwide 6. Current methods of diagnosing and treating MDD are symptom
based, that is, diagnosis is made based on the presence of symptoms outlined in the DSM 7
and successful treatment is defined by the reduction and eventual remission of those
symptoms 8. Relying on symptoms alone, without regard for the etiological roots of a
disorder, makes for mediocre diagnostic reliability 9-11 and inadequate treatment 12. The
effectiveness of anti-depressant pharmacotherapy is hampered by our limited understanding
of the biological basis of MDD 8, 13; indeed the administration of anti-depressant
medications results in remission in only one third of patients 14. Identifying risk variants for
depression would enhance our understanding of the etiology of MDD which in turn would
enable earlier and more reliable detection as well as, potentially, the development of new
and more effective therapies 15, 16.
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Heritability estimates of MDD vary around 0.37 1, 17, indicating a substantial influence of
genes on MDD risk. However, attempts to isolate specific genes which mediate MDD risk
have been met with difficulty 16, 18: meta-analysis suggests that many of the early candidate
gene studies were false positives 19, 20, and numerous genome-wide association (GWA)
studies, including the latest mega-analysis of over nine thousand depressed individuals from
the Psychiatric Genetics Consortium, have struggled to attain genome-wide significant
results 20-30. As a consequence it has been suggested that even larger sample sizes are
necessary for the identification of risk variants for MDD 30. However, linkage, a method
that ostensibly measures rare in addition to common variation, has isolated numerous
genome-wide significant loci in relatively small samples 31-34. Thus, while intuitively the
assertion that greater sample sizes are needed to isolate genes for MDD makes good sense
(particularly given that increasing sample size has worked for other disorders e.g.
schizophrenia 35), it is also possible that the degree of genetic (and also phenotypic)
heterogeneity is greater for MDD than for other disorders 36 and as a consequence
increasing sample sizes might only serve to compound the problem. Therefore a
complementary approach would be to focus on reducing genetic heterogeneity using, for
example, a family-based approach when searching for MDD risk genes.
In order to effectively account for the phenotypic heterogeneity associated with MDD it is
critical to develop optimal MDD phenotypes 30. MDD is typically treated as a categorical
trait, it is assumed that MDD reflects the tail end of an underlying normal distribution of
mood, and that diagnosis occurs when a threshold for liability is crossed. It seems plausible
that the genes which moderate behavior at the tail end of the distribution are the same as
those that underlie the regulation of normal mood37 and by dichotomizing the MDD
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distribution, we ignore a substantial proportion of variance that would contribute to genefinding efforts. Conceptualizing MDD as a continuous dimension would capture this
important information which would confer greater sensitivity and power to detect genes 38.
Thus, the present study, we report on univariate linkage and association analysis of a
dimensional scale of depression derived from the Past Major Depressive Episode section of
the Mini-International Neuropsychiatric Interview (MINI) within extended-pedigree data.

Methods
Participants

Author Manuscript

The sample comprised 1221 Mexican American individuals from extended pedigrees (132
families, average size 9.32 people, range = 1-129). The sample was 63% female and had a
mean age of 46.01 (SD = 15.10; range = 18-97). Individuals in this San Antonio Family
Study cohort have actively participated in research for over 18 years and were randomly
selected from the community with the constraints that they are of Mexican American
ancestry, part of a large family, and live within the San Antonio region (see (Olvera et al.,
2011) for recruitment details). All participants provided written informed consent on forms
approved by the institutional review board at the University of Texas Health Science Center
of San Antonio.
Diagnostic Assessment

Author Manuscript

All participants received the Mini-International Neuropsychiatric Interview (MINI) 39,
which is a semi-structured interview augmented to include items on lifetime diagnostic
history. Masters-and doctorate-level research staff, with established reliability (κ ≥ .85) for
affective disorders, conducted all interviews. All subjects with possible psychopathology
were discussed in case conferences that included licensed psychologists or psychiatrists.
Lifetime consensus diagnoses were determined based on available medical records, the
MINI interview, and the interviewer's narrative.
Data Analysis

Author Manuscript

Depression Modelling: Confirmatory Factor Analysis—All items from the Past
Major Depressive Episode (A3a-g) section of the MINI were modeled using a single factor
score; Table 1 outlines each of these items. This enabled the categorical outcomes associated
with the A3a-g MINI items to be modeled as a unitary quantitative trait. It is important to
note that because the factor model included all items from the past major depressive episode
section, the resultant score should be thought of as a lifetime rating of depression not a
reflection of current symptom severity. the Specifically, a single-factor model was built
using confirmatory factor analysis in Mplus (Figure 1). Family structure was taken into
account using the cluster command, under the cluster command in Mplus standard errors in
the model are adjusted in accordance with non-independence in the data, in this way family
ID is treated as a nuisance covariate. Because the questionnaire items have categorical rather
than continuous outcomes, factor analysis was applied to tetrachoric correlations derived
from the raw phenotypic data. The resultant factor score (mean = 0.15, standard deviation =
0.59) was subjected to an inverse normalization to ensure normality.
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Subjects were genotyped for approximately one million SNPs using Illumina
HumanHap550v3, HumanExon510Sv1, Human1Mv1 and Human1M-Duov3 BeadChips,
according to the Illumina Infinium protocol (Illumina, San Diego, CA). SNP loci were
checked for Mendelian consistency utilizing SimWalk2 (Sobel and Lange, 1996). SNPs or
samples exhibiting high calling rate failures or requiring excessive blanking (i.e., if <95% of
the genotypes are retained) were eliminated from analyses. Missing genotypes were imputed
according to Mendelian laws based on available pedigree data using MERLIN (Abecasis et
al., 2002). Maximum likelihood techniques, accounting for pedigree structure, were used to
estimate allelic frequencies (Boehnke, 1991). For linkage analyses, multipoint identity-bydescent (IBD) matrices were calculated based on 28,387 SNPs selected from the 1M GWAS
panel as follows. Using genotypes for 345 founders, SNPs on each chromosome were
selected to be at least 1kb apart, MAF >= 5%, and LD within a 100kb sliding window not
exceeding |rho| = 0.15. The resulting selection averaged 7-8 SNPs/centimorgan. For each
centimorgan location in the genome, multipoint IBD probability matrices were calculated
using a stochastic Markov Chain Monte Carlo procedure implemented in the computer
package, LOKI (Heath, 1997).
Quantitative Genetic Analyses

Author Manuscript

All genetic analyses were performed in SOLAR 40. SOLAR implements a maximum
likelihood variance decomposition to determine the contribution of genes and environmental
influence to a trait by modeling the covariance among family members as a function of
expected allele sharing given the pedigree. In the simplest such decomposition, the additive
genetic contribution to a trait is represented by the heritability, or h2, index. Univariate
variance decomposition analysis was applied to the continuous measure of depression. The
trait was normalized using an inverse Gaussian transformation. Age, age2, sex and their
interactions were included as covariates.
Linkage and Association Analyses

Author Manuscript

Quantitative trait linkage analysis was performed to localize specific chromosomal locations
influencing MDD 40. Model parameters were estimated using maximum likelihood. The
hypothesis of significant linkage was assessed by comparing the likelihood of a classical
additive polygenic model with that of a model allowing for both a polygenic component and
a variance component due to linkage at a specific chromosomal location (as evidenced by
the location-specific identity-by-descent probability matrix). The LOD score, given by the
log10 of the ratio of the likelihoods of the linkage and the polygenic null models, served as
the test statistic for linkage. Genome-wide thresholds for linkage evidence were computed
for this exact pedigree structure and density of markers, using a method derived from 41: a
LOD of 1.69 is required for suggestive significance (likely to happen by chance less than
once in a genome-wide scan) and a LOD of 2.9 is required for genome-wide significance.
Genomic regions meeting genome-wide significance for linkage were investigated in greater
detail using association analysis of the MDD confirmatory factor score and the genetic
variants encapsulated by the linkage peak. Statistical significance levels were established
according to the effective number of tested variants given the linkage disequilibrium (LD)
J Affect Disord. Author manuscript; available in PMC 2017 February 01.
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structure in the region. To this end, the pairwise genotypic correlations were calculated in an
effort to establish the effective number of independent tests carried out during association
analysis. This method, by Moskvina and Schmidt 42, is considered to be conservative and
entails computing the eigenvalues of the genotypic correlation matrix. A corrected P-value is
obtained from a Bonferroni correction based on the nominal alpha (=0.05) and the total
number of independent tests.
Results
Confirmatory Factor Analysis—All MINI items were shown to be significantly
heritabile (Table 1). The bivariate tetrachoric correlations (see Table S1) were uniformly
moderate to high with little discriminability between items, suggesting a single underlying
dimension. A one-factor model fit the data excellently (χ212 = 13.82 p = 0.129, RMSEA = .
020 (.000 - .040) p = 0.995, CFI = 1.000, TLI = 1.000, WRMR = .617).

Author Manuscript

Heritability and Linkage Analysis
The score derived from the factor model was deemed to be significantly heritable (h2 = 0.21,
p = 2.3×10-05). Significant univariate linkage was detected for the depression trait on
chromosome 10 at 153cM (LOD = 3.43; Figure 2). The majority of this linkage signal
originated from a single multiplex MDD pedigree within the data (h2 = 0.33, p = 1.7×10-02,
LOD = 1.54) and the top LOD for the multiplex pedigree within the region encapsulated by
the linkage peak met the criteria for suggestive significance (LOD = 1.84, 152cM).
Association Analysis

Author Manuscript
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Association analysis was conducted using all variants within the linkage peak (defined as
150-154cM) and the continuous factor score of (Table 2 and Figure 3), the peak-wide (LDadjusted Bonferroni-corrected) significance level = 8.7×10-05 (975 SNPs, 590.69 effective
SNPs). For association analysis run in the entire sample, the top-ranked variant was
suggestively significant (rs11245316, χ2 = 11.28, p = 7.8×10-04) and located within an
intron of the gene LHPP (phospholysine phosphohistidine inorganic pyrophosphate
phosphatase). Association analysis run only in the multiplex MDD pedigree from which the
majority of the linkage signal originated revealed a variant that met peak-wide significance
(rs7913161, χ2 = 17.84, p = 2.4×10-05) within an intron of the gene CPXM2
(carboxypeptidase X (M14 family), member 2). When the SNP rs7913161 was included as a
covariate in the linkage analysis of the continuous depression factor score in the multiplex
pedigree, the LOD score observed without the covariate (LOD = 1.84) was reduced
substantially (LOD = 0.46). This linkage conditional on association test gives additional
support for the involvement of rs7913161 in depression risk within the multiplex MDD as it
implicates the variant in the linkage model for MDD within the pedigree. Association for
this variant was not significant in either the entire sample (χ2 = 1.68, p = 0.19) or in any
other individual pedigree (the next best association for rs7913161 in any other pedigree did
not reach suggestive significance, χ2 = 3.97, p = 0.04), suggesting that the variant is likely
marking a functional and rare variant present only in the multiplex pedigree.
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The factor score derived from the one-factor model of depression correlates highly with the
analogous dichotomous diagnosis of depression (indicating the presence or absence of a
depressive episode over the lifetime of an individual), derived from the same section of the
MINI (rphenotypic = 0.87 (p = 1.22×10-217), rgenetic = 1.00 (p = 2.46×10-06)). This high
correlation is unsurprising given that the two traits are derived from precisely the same
items. However, to provide further validation of the factor model, we ran linkage analysis
for the dichotomous diagnostic trait within the region of chromosome 10 where we observed
a genome-wide significant peak for the continuous factor score. For this analysis, the
dichotomous diagnostic trait was transformed into a normally-distributed liability trait based
on disease prevalence following standard quantitative genetic practice 43 (pp. 299-309). The
analogous liability measure from the same items in the entire sample did not exhibit
genome-wide significant linkage but neared suggestive significance (h2 = 0.38, p =
4.7×10-06, LOD = 1.58 at 153cM; Figure 2). Moreover, association analysis with the top
ranked variant (for the continuous factor score) and the dichotomous measure exhibited
some signal without reaching suggestive significance (χ2= 3.93, p = 4.7×10-02), while the
top-ranked variant (in the multiplex pedigree) also reached significance for the dichotomous
measure of depression (χ2= 16.23, p = 5.6×10-05). Thus, while the continuous measure of
depression derived from the single-factor model overlaps almost completely with the
dichotomous measure derived from the same items; the use of a continuous measure was
shown to be more successful for gene-finding efforts. It is of note that the distribution of our
continuous factor score is bimodal which is in line with a number of unaffected individuals
within the data. Indeed, the kurtosis score (-0.5887) indicates a platykurtic distribution.
However, previous work indicates that positive kurtosis, not negative, may inflate the falsepositive rate for linkage 44, 45. Nonetheless, we ran an emprical LOD adjustment routine in
SOLAR which calculates an adjustment factor by which to multiply the peak LOD from
linkage analysis; 10,000 simulations run on the inverse normalized factor score calculated an
adjustment factor of 1.08 where an adjustment factor > 1 means that our LOD of 3.43 is in
fact somewhat conservative. Thus, we are satisfied that our trait, despite being negatively
skewed, has not resulted in an inflated LOD score in the present paper.

Discussion

Author Manuscript

Repeated attempts to identify genetic influences on MDD using genome-wide association
have been met with difficulty. Conversely, several genome-wide significant loci have been
identified using linkage analysis 32, 33, including in the same region of chromosome 10, and
more specifically in the same gene LHPP, as identified here 31. Moreover, a recent whole
genome sequence study has also highlighted the role of the gene LHPP in MDD risk 46. The
present study extends the previous literature by supporting the role of 10q26.13 (and
possibly LHPP) in risk for MDD. Moreover, the present study identifies a novel and
interesting gene, CPXM2, in a newly identified large multiplex MDD pedigree from whom
the majority of the linkage signal originates – though this finding needs replication before it
can be considered a risk gene for MDD. The linkage conditional on association test for the
variant within CPXM2 suggests that it is partially responsible (either directly or via LD with
another variant) for the linkage signal within the multiplex pedigree 47. Indeed, it is likely
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that the variant identified in the pedigree is marking a functional and rare variant that exists
only in this pedigree. Thus, the present study, through a combination of linkage in extended
pedigrees and a dimensional index of depression, highlights a two interesting genes for
MDD risk and, potentially, the role of rare variation in risk for the illness.

Author Manuscript

LHPP encodes the protein phospholysine phosphohistidine inorganic pyrophosphate
phosphatase (Lhpp) 48 and is highly expressed in brain 31, 49. Neff and colleagues have
previously implicated the gene LHPP in MDD risk using a combination of linkage and
association analysis 31. However, the LHPP associations were dependent on HTR1A
genotype, which is not a finding that we were able to replicate in the present paper. First,
many of the LHPP variants identified by Neff and colleagues as being associated with MDD
risk are not present in our sample, although those that are present are in partial LD with our
top-ranked variant (rs12265012, r2 = 0.21; rs10794134, r2 = 0.17) 31. Second, while Neff
and colleagues showed an interaction between HTR1A (and specifically the 1019C>G
genotype, rs2495, which is not present in out sample) and LHPP, we did not. Three HTR1A
variants are present in our sample, and an interaction term between our top-ranked LHPP
variant and any of the HTR1A variants was not significant when included as covariates in a
polygenic model of the depression factor score (rs10052087, χ2= 0.75, p = 0.39; rs6449693,
χ2= 0.01, p = 0.93; rs6294, χ2= 0.75, p = 0.39); and none of the HTR1A variants were
significantly associated with the continuous depression score in isolation (rs10052087, χ2=
0.46, p = 0.50; rs6449693, χ2= 2.16, p = 0.14; rs6294, χ2= 0.46, p = 0.50). Relatively little is
known about the function of LHPP. A single study implicates the role of Lhpp in thyroid
function 50, which could be interesting given that thyroid function is thought to mediate the
function of certain anti-depressants 51. However, an explicit relationship between thyroid
function, Lhpp and MDD is not apparent based on current research.
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The gene CPXM2 is a member of the metallocarboxypeptidase A family of digestive
enzymes and is highly expressed in brain, particularly in the hippocampus, hypothalamus,
choroid plexus and throughout the cerebral cortex 52. CPXM2 is distinct from other genefamily members as it lacks the active site residues necessary for enzyme function and as a
consequence it may fulfill an alternative role as a phospholipid binding protein 53. In rats
CPE, a paralog of CPXM1 (which is highly similar to CPXM2 in that it also lacks the
catalytic activity found in other carboxypetidases 54), mediates dopamine transporter (DAT)
expression such that co-expression of CPE and DAT results in increased dopamine reuptake
in brain 55. Also, a variant of CPXM2 is suggestively associated with cognitive decline in
schizophrenia 56, where cognitive ability, and more specifically cognitive impairment in
schizophrenia, is thought to be modulated by dopaminergic signaling 57-59. Insofar as the
role of dopamine is well established in MDD 60-62 and that the gene CPXM2, or at least very
similar genes in the same family, appears to influence dopamine functioning in the brain, the
present paper highlights a new candidate gene for MDD in a newly established large
multiplex MDD pedigree that warrants further investigation.
The association for the variant rs7913161 in CPXM2 in the larger sample was low and not
significant, which could suggests that the variant is marking a rare and functional variant
that exists only within the multiplex MDD pedigree, one which likely makes up a haplotype
of many variants. The authors of the most recent mega-analysis GWA study (GWAS) from
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the PGC, which comprised approximately seventy thousand subjects, cite the need for even
greater sample sizes and increased power in order to detect genetic variants for
depression 30. However, it is also possible that genetic heterogeneity for MDD is greater
than for other disorders, meaning that it will be necessary to reduce genetic heterogeneity
(for example, by studying a group of genetically-homogenous kindred) in order to find risk
genes. The present study makes a case for the latter approach; namely, the use of whole
genome sequence data in extended pedigrees. The common disease-rare variant hypothesis
states that the genetic causes of common, polygenic disorders such as depression are likely
to be rare in the population. Clearly the use of rare variation alone will not solve the power
issues highlighted by the PGC. However, identifying a rare functional variant (with a large
effect size) in only a handful of affected individuals can be sufficient to verify that a given
gene is involved in an illness. Data from the 1000 Genomes Project confirm that rare (<1%)
variants constitute the vast majority (73%) of polymorphic sites in humans 63. A key factor
for identification of specific rare functional variants is detecting sufficient copies of that
variant for statistical inference 64, 65. Pedigree-based studies represent an implicit
enrichment strategy for identifying rare variants as Mendelian transmissions from parents to
offspring maximize the chance that multiple copies of rare variants exist in the pedigree.
Family-based cohorts have substantially greater power than unrelated cases to detect rare
genetic effects given an equivalent number of sampled individuals 66, 67. For example, genes
for hypertension have been identified for blood pressure in the general population by
focusing research efforts on an extended pedigree with a rare form of hypertension 68.
Indeed, rare deleterious mutations are known to occur in genes that also harbor common
variants with modest effects on disease risk 69. For example, 11 of 30 genes with common
variants associated with lipid levels also carry known rare alleles of large effect in
Mendelian dyslipidemias 70, 71. Furthermore, rare variants may contribute to loci identified
through common variation 72.

Author Manuscript

Another issue the PGC highlights in the hunt for depression genes is the possibility that the
depression phenotypes used in genetic studies are ‘suboptimal’ 30 (p. 9). This observation
dovetails with the Research Domain Criteria (RDoC) strategy that was recently proposed by
the NIMH. This strategy encourages researchers to focus their efforts on developing new
ways of classifying psychopathology by developing a dimension-based taxonomy of
functioning that encompasses behavior, neuroscience and genetics 73, 74. MDD is typically
treated as a categorical trait it is assumed that MDD reflects the tail end of an underlying
normal distribution of mood, and that diagnosis occurs when a threshold for liability is
crossed. It seems plausible that the genes which moderate behavior at the tail end of the
distribution are the same as those that underlie the regulation of normal mood 37 and by
dichotomizing the MDD distribution, we ignore a substantial proportion of variance that
would contribute to gene-finding efforts. Thus the present paper is in line with the RDoC
strategy whereby depression is represented as a continuum or dimension and moreover the
use of a continuous measure of depression derived from a single-factor model of interview
items versus the analogous dichotomous measure from the same items was shown to be
more successful in the present study. The notion that continuous models of complex
disorders derived from commonly used questionnaires can be used in association studies
represents a significant advancement over studies that rely entirely on a diagnostic endpoint.
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Other studies have examined this notion in detail, and developed multidimensional models
of depressive symptomatology 75-77. The present work focussed specifically on the MINI
and as such fewer dimensions were derived (indeed, inspection of the correlations between
items strongly supports the existence of a single dimension in the data used in the present
study; Table S1), however the utility of the present study over those published previously is
the inclusion of genetic data which allowed the identification of possible candidate genes
(LHPP and CPXM2).

Author Manuscript

In summary, the present study represents advancement in our understanding in the genetics
of depression in two ways. First, it confirms the probable involvement of a gene previously
implicated in illness risk (LHPP) and, through the use of a multiplex MDD pedigree, it
highlights a novel risk gene (CPXM2), which warrants further investigation. Second, it
draws attention to an alternative methodology for the hunt for depression genes, which is
focusing on rare variation in a multiplex MDD pedigree combined with the use of
dimensional indices of MDD symptomatology.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

One-factor confirmatory factor model of all items from the past major depressive episode
section of the MINI.
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Figure 2.

Chromosome 10 multipoint plot for the univariate linkages of the continuous depression
factor score (dark blue) and also the dichotomous measure of depression derived from
precisely the same items (light blue).
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Figure 3.

QTL-specific association analysis within the QTL on chromosome 10 for the continuous
depression factor score in the entire sample (blue) and the multiplex MDD pedigree (green).
The top plot shows the linkage signal in the entire sample and the multiplex pedigree. The
plot below shows the results of association analysis in the same region. Intergenic regions
are pale gray and genes are represented by the dark gray bars. The top ranked variant in each
subject group is represented by a diamond and the degree of linkage disequilibrium is
represented by the color scale.
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Descriptive statistics for each item for the past major depressive episode section of the MINI.
When you felt depressed or uninterested:

% Responded No

h2

SE

Was your appetite decreased or increased nearly every day? Did your weight decrease or increase without
trying intentionally?

.663

.270

.074

Did you have trouble sleeping nearly every night?

.659

.203

.087

Did you talk or move more slowly than normal or were you fidgety, restless or having trouble sitting still
almost every day?

.725

.177

.243

Did you feel tired or without energy almost every day?

.691

.290

.074

Did you feel worthless or guilty almost every day?

.730

.193

.224

Did you have daily difficulty concentrating or making decisions?

.744

.245

.100

Did you repeatedly consider hurting yourself, feel suicidal, or wish that you were dead?

.840

.339

.153
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χ2

11.28

9.09

7.51

7.38

7.30

17.84

16.19

15.35

14.28

14.17

SNP

rs11245316

rs3884528

rs4578341

rs1123988

rs859556

rs7913161

rs4995180

rs7906808

rs7906939

rs7095366

0.000167

0.000158

0.000089

0.000057

0.000024

0.00688

0.00658

0.006127

0.002565

0.000783

p-value

0.006

0.007

0.008

0.008

0.009

Variance Explained

1.18

1.52

1.95

1.35

0.69

0.116

0.131

0.133

0.139

0.150

Multiplex Pedigree

-0.58

0.11

0.12

-0.11

0.15

β

Entire Sample

0.021

0.010

0.006

0.025

0.163

0.006

0.006

0.219

0.466

0.213

MAF

0.51

0.69

0.66

0.45

0.38

0.96

0.86

0.98

0.18

0.88

HWE p-value

Estimates for the Top Five SNPs from the QTL-specific Association Analysis in (a) the Entire Sample and (b) the Multiplex MDD Pedigree for the
Continuous Depression Score.
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